These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26732860)
1. The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. Chiriaco M; Brigida I; Ariganello P; Di Cesare S; Di Matteo G; Taus F; Cittaro D; Lazarevic D; Scarselli A; Santilli V; Attardi E; Stupka E; Giannelli S; Fraziano M; Finocchi A; Rossi P; Aiuti A; Palma P; Cancrini C Clin Immunol; 2017 May; 178():20-28. PubMed ID: 26732860 [TBL] [Abstract][Full Text] [Related]
2. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome. Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M Front Immunol; 2018; 9():568. PubMed ID: 29675019 [TBL] [Abstract][Full Text] [Related]
4. Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Wentink M; Dalm V; Lankester AC; van Schouwenburg PA; Schölvinck L; Kalina T; Zachova R; Sediva A; Lambeck A; Pico-Knijnenburg I; van Dongen JJ; Pac M; Bernatowska E; van Hagen M; Driessen G; van der Burg M Clin Immunol; 2017 Mar; 176():77-86. PubMed ID: 28104464 [TBL] [Abstract][Full Text] [Related]
6. Exhaustion of the CD8 Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD Front Immunol; 2018; 9():446. PubMed ID: 29563914 [TBL] [Abstract][Full Text] [Related]
7. A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects. Bildik HN; Esenboga S; Halaclı SO; Karaatmaca B; Aytekin ES; Nabiyeva N; Akarsu A; Ocak M; Erman B; Tan C; Arikoglu T; Yaz I; Cicek B; Tezcan I; Cagdas D Pediatr Allergy Immunol; 2024 Sep; 35(9):e14245. PubMed ID: 39312287 [TBL] [Abstract][Full Text] [Related]
8. A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1). Lougaris V; Baronio M; Moratto D; Tampella G; Gazzurelli L; Facchetti M; Martire B; Cardinale F; Lanzarotto F; Bondioni MP; Villanacci V; Grimbacher B; Plebani A Clin Immunol; 2019 Mar; 200():31-34. PubMed ID: 30639166 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome. Del Pino-Molina L; Torres Canizales JM; Rodríguez-Pena R; López-Granados E Cytometry B Clin Cytom; 2021 Jul; 100(4):460-466. PubMed ID: 32961022 [TBL] [Abstract][Full Text] [Related]
10. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome. Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677 [TBL] [Abstract][Full Text] [Related]
12. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome. Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059 [TBL] [Abstract][Full Text] [Related]
13. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755 [TBL] [Abstract][Full Text] [Related]
14. Increased expression of the PI3K catalytic subunit p110δ underlies elevated S6 phosphorylation and protein synthesis in an individual with autism from a multiplex family. Poopal AC; Schroeder LM; Horn PS; Bassell GJ; Gross C Mol Autism; 2016; 7():3. PubMed ID: 26770665 [TBL] [Abstract][Full Text] [Related]
15. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962 [TBL] [Abstract][Full Text] [Related]
16. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. Michalovich D; Nejentsev S Front Immunol; 2018; 9():369. PubMed ID: 29535736 [TBL] [Abstract][Full Text] [Related]
17. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib. Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011 [TBL] [Abstract][Full Text] [Related]